» Articles » PMID: 36332007

Hypodiploidy Has Unfavorable Impact on Survival in Pediatric Acute Myeloid Leukemia: an I-BFM Study Group Collaboration

Abstract

Hypodiploidy, defined as modal numbers (MNs) 45 or lower, has not been independently investigated in pediatric acute myeloid leukemia (AML) but is a well-described high-risk factor in pediatric acute lymphoblastic leukemia. We aimed to characterize and study the prognostic impact of hypodiploidy in pediatric AML. In this retrospective cohort study, we included children below 18 years of age with de novo AML and a hypodiploid karyotype diagnosed from 2000 to 2015 in 14 childhood AML groups from the International Berlin-Frankfurt-Münster (I-BFM) framework. Exclusion criteria comprised constitutional hypodiploidy, monosomy 7, composite karyotype, and t(8;21) with concurring sex chromosome loss. Hypodiploidy occurred in 81 patients (1.3%) with MNs, 45 (n = 66); 44 (n = 10) and 43 (n = 5). The most frequently lost chromosomes were chromosome 9 and sex chromosomes. Five-year event-free survival (EFS) and overall survival (OS) were 34% and 52%, respectively, for the hypodiploid cohort. Children with MN≤44 (n = 15) had inferior EFS (21%) and OS (33%) compared with children with MN = 45 (n = 66; EFS, 37%; OS, 56%). Adjusted hazard ratios (HRs) were 4.9 (P = .001) and 6.1 (P = .003). Monosomal karyotype or monosomy 9 had particular poor OS (43% and 15%, respectively). Allogeneic stem cell transplantation (SCT) in first complete remission (CR1) (n = 18) did not mitigate the unfavorable outcome of hypodiploidy (adjusted HR for OS was 1.5; P = .42). We identified pediatric hypodiploid AML as a rare subgroup with an inferior prognosis even in the patients treated with SCT in CR1.

Citing Articles

Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML.

Maceckova D, Vankova L, Holubova M, Jindra P, Klieber R, Jandova E Mol Biol Rep. 2024; 51(1):521.

PMID: 38625438 DOI: 10.1007/s11033-024-09452-2.


Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia.

Tomizawa D, Tsujimoto S Cancers (Basel). 2023; 15(16).

PMID: 37627199 PMC: 10452723. DOI: 10.3390/cancers15164171.

References
1.
Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C . Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol. 2017; 177(1):116-126. DOI: 10.1111/bjh.14523. View

2.
Tsukamoto M, Matsuyama H, Oba K, Yoshihiro S, Takahashi M, Naito K . Numerical aberrations of chromosome 9 in bladder cancer. A possible prognostic marker for early tumor recurrence. Cancer Genet Cytogenet. 2002; 134(1):41-5. DOI: 10.1016/s0165-4608(01)00618-5. View

3.
Harrison C, Hills R, Moorman A, Grimwade D, Hann I, Webb D . Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010; 28(16):2674-81. DOI: 10.1200/JCO.2009.24.8997. View

4.
von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts D . Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010; 28(16):2682-9. DOI: 10.1200/JCO.2009.25.6321. View

5.
Grimwade D, Hills R, Moorman A, Walker H, Chatters S, Goldstone A . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-65. DOI: 10.1182/blood-2009-11-254441. View